Drug Profile
Emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences
Alternative Names: Emtricitabine/tenofovir-disoproxil; Emtriva®/Viread®; FTC/TDF; TDF/FTC; Tenofovir disoproxil fumarate/emtricitabine; Truvada; TVD; Viread®/Emtriva®Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gador; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; Stendhal Mexico; University of Alberta; University of Washington
- Class Antiretrovirals; Deoxyribonucleosides; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides
- Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
- Phase III Hepatitis B
- Phase II Primary biliary cirrhosis
Most Recent Events
- 01 Jan 2024 University of Alberta in collaboration with Merck Sharp & Dohme completes a phase II trial in Primary biliary cirrhosis (Combination therapy) in Canada (PO) (NCT03954327)
- 26 Oct 2023 Gilead Sciences plans a phase II PURPOSE-4 trial for HIV Infection (Prevention, Combination therapy) in December 2023 (NCT06101342)
- 19 Feb 2023 Initial pharmacokinetics and safety data from a phase IIIb trial in HIV infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)